Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
From ImmunoPrecise Antibodies
Via Business Wire
Healthcare and AI “Paradigm Shift” Stocks in Focus: IPA, MGRX, INBS, RMED
Via AB Newswire
Topics Artificial Intelligence
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) Is Strategically Built To Advance The Future
Via AB Newswire
Topics Artificial Intelligence
News headline image
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
From ImmunoPrecise Antibodies
Via Business Wire
‘Baby with the Bathwater’ Biotechs (IPA, NRXP, PRFX, LEXX, LQDI)
Via AB Newswire
News headline image
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA to Present at Jefferies Healthcare Conference 2023
From ImmunoPrecise Antibodies
Via Business Wire
The Street Reports: NASDAQ Stocks Poised to Disrupt the Markets: IPA, RELI, SKYX, AZ
Via AB Newswire
Topics Artificial Intelligence
TheStreetReports: AI Biotech Stocks to Watch 2023: IPA, ONTX, AGEN, PBIO
Via AB Newswire
Topics Artificial Intelligence
News headline image
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
News headline image
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
From ImmunoPrecise Antibodies
Via Business Wire
Immunity Focused Biotherapeutic Developer with a Hybrid of Services and Technology for a Wide Range of Applications: ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)
Via Get News
Topics Artificial Intelligence
Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
Via AB Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.